AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$IRON

Yu Jonathan Yen-Wen sold $756K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 9,096 shares of Disc Medicine, Inc. (IRON) at an average of $83.10 ($82.53–$83.12, $0.76M total) across 2 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Aug 27, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 1:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
medium confidence
Mentioned
$IRON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but may attract short interest.

02

Market read

Routine insider sale with limited market impact.

03

What to watch

COO may be diversifying personal portfolio; no change in company fundamentals.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-08-26

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$IRONNeutralMedium confidence
Context

COO Yu Jonathan Yen-Wen sold 9,096 shares for $756K via a 10b5-1 plan, reducing his stake to 54,324 shares.

Expected impact

Potential short-term downward pressure, limited impact due to low volume.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of total shares; market may view as routine.

Market effects

Sector

Minimal effect on biotech sector; insider sales are common.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be a strategic reallocation rather than lack of confidence.

Key entities

  • Company
    Disc Medicine, Inc.

    Biotech firm focused on drug development.

  • Insider
    Yu Jonathan Yen-Wen

    Chief Operating Officer of Disc Medicine.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRON insider trading history →

Related articles

$IRONHighAI 9/10

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e

SEC EDGAR 8-K
$IRONHighAI 9/10

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on

SEC EDGAR 8-K
$IRONHighAI 8/10

Why is Disc Medicine stock sliding today?

Disc Medicine (IRON) stock fell 1.0% in pre-market trading after pricing a $450M public offering of 6M shares at $75 each, a discount to recent prices. The offering, with potential for additional shares, may dilute existing holders. Proceeds will fund clinical development and general corporate purposes. Analysts recently raised price targets following positive trial results, but insiders have been net sellers.

investing.com